Deutsche Bank AG Has $56.75 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Deutsche Bank AG boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,778,377 shares of the company's stock after purchasing an additional 30,867 shares during the period. Deutsche Bank AG owned about 1.43% of Apellis Pharmaceuticals worth $56,748,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in APLS. Xponance Inc. lifted its position in Apellis Pharmaceuticals by 5.6% during the 4th quarter. Xponance Inc. now owns 14,072 shares of the company's stock worth $449,000 after buying an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 2,707.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company's stock worth $25,000 after purchasing an additional 758 shares in the last quarter. Signaturefd LLC lifted its position in shares of Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company's stock worth $37,000 after purchasing an additional 918 shares in the last quarter. US Bancorp DE grew its stake in shares of Apellis Pharmaceuticals by 70.0% during the fourth quarter. US Bancorp DE now owns 3,223 shares of the company's stock valued at $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its holdings in shares of Apellis Pharmaceuticals by 9.4% in the fourth quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company's stock valued at $691,000 after purchasing an additional 1,864 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Up 1.3%

NASDAQ:APLS opened at $17.52 on Tuesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business's 50-day simple moving average is $21.15 and its 200-day simple moving average is $27.05. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $43.99. The stock has a market capitalization of $2.20 billion, a PE ratio of -8.63 and a beta of 0.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $149.90 million for the quarter, compared to analyst estimates of $197.61 million. During the same quarter last year, the business posted ($0.54) earnings per share. The business's quarterly revenue was down 3.2% on a year-over-year basis. Sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on APLS shares. Wedbush decreased their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. Cantor Fitzgerald began coverage on Apellis Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $44.00 price objective for the company. Needham & Company LLC cut their target price on shares of Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Finally, Scotiabank reduced their target price on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a "sector perform" rating on the stock in a research note on Thursday, May 8th. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Apellis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $41.37.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the sale, the general counsel now owns 138,730 shares of the company's stock, valued at $3,482,123. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 6.50% of the stock is currently owned by insiders.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.